Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | PPARD | Q03181 | 5/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968566 | 0.89 | HRH3 (0.42) | HRH3KDM4EALDH1A1TP53TSHR | |
| SCHEMBL3193386 | 0.89 | RAB9A (0.45) | KDM4EALDH1A1TSHR | |
| SCHEMBL3081651 | 0.88 | KDM1A (0.43) | PPARDFFAR1ALDH1A1 | |
| SCHEMBL3085349 | 0.88 | KMT2A (0.50) | HRH3KDM4EPPARGPPARDFFAR1 | |
| SCHEMBL3072493 | 0.88 | HRH3 (0.49) | HRH3KDM4EPPARGPPARDFFAR1 | |
| SCHEMBL6041843 | 0.87 | RAB9A (0.45) | HRH3KDM4EALDH1A1TSHR | |
| SCHEMBL3084820 | 0.87 | PDE4B (0.46) | HRH3KDM4ETP53 | |
| SCHEMBL6043844 | 0.86 | MEN1 (0.45) | ALDH1A1TSHR | |
| SCHEMBL3072128 | 0.85 | KDM1A (0.42) | HRH3PPARGPPARDFFAR1ALDH1A1 | |
| SCHEMBL3072157 | 0.85 | KDM4E (0.47) | HRH3KDM4EPPARGPPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | HRH3 1653/4885KDM4E 1843/4885PPARG 258/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | HRH3 1653/4885KDM4E 1843/4885PPARG 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.